IMRIS (OTCMKTS:IMRSQ – Get Free Report) and Electromed (NYSE:ELMD – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.
Insider and Institutional Ownership
40.8% of Electromed shares are held by institutional investors. 14.0% of Electromed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for IMRIS and Electromed, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
IMRIS | 0 | 0 | 0 | 0 | 0.00 |
Electromed | 0 | 0 | 0 | 1 | 4.00 |
Profitability
This table compares IMRIS and Electromed’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
IMRIS | N/A | N/A | N/A |
Electromed | 11.34% | 15.71% | 13.37% |
Earnings and Valuation
This table compares IMRIS and Electromed”s top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
IMRIS | N/A | N/A | N/A | N/A | N/A |
Electromed | $59.63 million | 3.84 | $5.15 million | $0.75 | 35.68 |
Electromed has higher revenue and earnings than IMRIS.
Summary
Electromed beats IMRIS on 9 of the 9 factors compared between the two stocks.
About IMRIS
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.
About Electromed
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Receive News & Ratings for IMRIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMRIS and related companies with MarketBeat.com's FREE daily email newsletter.